Prot #CAB-201-003: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Systemic Sclerosis

Project: Research project

Project Details

StatusActive
Effective start/end date4/1/249/13/27

Funding

  • Advanced Clinical LLC (Prot #CAB-201-003 // Prot #CAB-201-003)
  • Cabaletta Bio, Inc. (Prot #CAB-201-003 // Prot #CAB-201-003)